Search
Tiotropium
go.drugbank.com/drugs/DB01409ApprovedInvestigationalTiotropium is a long-acting, antimuscarinic bronchodilator used in the management of chronic obstructive pulmonary disease (COPD) and asthma. … [A180163,L7084,L7087,L7090,L7093] Tiotropium is more specific for the subset of muscarinic receptors commonly found in the lungs than [ipratropium].
Orforglipron
go.drugbank.com/drugs/DB18964ApprovedInvestigationalOrforglipron is a first-in-class oral, non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist. … [L56123] On April 1, 2026, the US FDA granted approval to orforglipron for use alongside diet and exercise to aid in weight reduction in certain patient populations.
Viomycin
go.drugbank.com/drugs/DB06827ApprovedThese drugs bind RNA in bacterial ribosomes and inhibit protein synthesis. Viomycin was derived from the actinomycete _Streptomyces puniceus_. … Viomycin is a tuberactinomycin antibiotic that was used to treat Mycobacterium tuberculosis until it was replaced by the less toxic capreomycin.
Leniolisib
go.drugbank.com/drugs/DB16217ApprovedInvestigational[L45753] Investigations for using leniolisib in primary Sjögren’s syndrome are ongoing.[A258468] … [L45758] APDS is a primary immunodeficiency caused by mutations in genes encoding the PI3Kδ, thereby increasing the activity of PI3Kδ, causing immune dysfunction, and elevating susceptibility to infections
Ripasudil
go.drugbank.com/drugs/DB13165InvestigationalIt was first approved for treatment in Japan in September 2014. This medication is available in the form of a 0.4% eye drop solution under the brand name Glanatec. … Ripasudil is a well tolerated medication that is used when other drugs have been proven to be non-effective or cannot be administered.
Categories: Sympathomimetics in Glaucoma TherapyMaraviroc
go.drugbank.com/drugs/DB04835ApprovedInvestigationalIt was originally labelled as UK-427857 during development but was assigned the Maraviroc name as it entered trials. It was approved for use by the FDA in August, 2007. … Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the
Vibegron
go.drugbank.com/drugs/DB14895ApprovedInvestigationalOn December 23, 2020, vibegron was approved for the same indication in adults. It is available as oral tablets under the market name GEMTESA. … [L28305] Vibegron was first approved in Japan in September 2018 for the treatment of overactive bladder,[A226050] a condition associated with distressing symptoms of urge urinary incontinence, urgency,
Epoprostenol
go.drugbank.com/drugs/DB01240ApprovedInvestigationalA prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue.
Synonyms: Prostaglandin I2Categories: Prostaglandins ITreprostinil
go.drugbank.com/drugs/DB00374ApprovedInvestigational[L41860] It is available in the following routes of administration: subcutaneous, intravenous, inhaled and oral. The first generic form of treprostinil became available in 2019.[A248775] … Treprostinil was approved by the FDA in 2002 for the treatment of pulmonary arterial hypertension.
Categories: Prostaglandins INetupitant
go.drugbank.com/drugs/DB09048ApprovedInvestigationalNetupitant is an antiemitic drug approved by the FDA in October 2014 for use in combination with palonosetron for the prevention of acute and delayed vomiting and nausea associated with cancer chemotherapy … Netupitant is a neurokinin 1 receptor antagonist. The combination drug is marketed by Eisai Inc. and Helsinn Therapeutics (U.S.) Inc. under the brand Akynzeo.
Synonyms: 2-[3,5-Bis(trifluoromethyl)phenyl]-N,2-dimethyl-N-[4-(2-methylphenyl)-6-(4-methyl-1-piperazinyl)-3-pyridinyl]propanamide